| Autor: |
Joab Trajano Silva, E. M. Del Aguila, P.M. Sousa, V. M. F. Paschoalin, G.F. Asensi, J.M. Cavalcanti, L.R. Castilho |
| Rok vydání: |
2005 |
| Předmět: |
|
| Zdroj: |
Animal Cell Technology Meets Genomics ISBN: 9781402027918 |
| DOI: |
10.1007/1-4020-3103-3_94 |
| Popis: |
Since mammalian cells are able to correctly carry out protein folding and glycosylation, they are the host of choice for the expression of human glycoproteins of therapeutic use. Currently approved biopharmaceuticals derived from mammalian cell culture include monoclonal antibodies, blood coagulation factors, colony stimulating factors and other recombinant proteins (Castilho and Medronho, 2002). Factor IX (FIX) is a coagulation glycoprotein that is either absent or deficient in hemophilia B patients. Administration of recombinant Factor IX to patients does not present the risk of virus contamination associated with hemodialysis or with Factor IX derived from human plasma. Human granulocyte colony stimulating factor (GCSF) is a cytokine that stimulates the proliferation and terminal differentiation of neutrophilic granulocytes from progenitor cells. Therefore, G-CSF is employed in the treatment of illnesses such as neutropenia and leucopenia. The aim of the present work was to construct recombinant vectors to be employed in the transfection of CHO.K1 and BHK-21 cells, in order to obtain recombinant cell lines stably expressing human Factor IX and G-CSF. |
| Databáze: |
OpenAIRE |
| Externí odkaz: |
|
